Latest Commercial Partnerships News

Page 3 of 22
Helloworld Travel (ASX:HLO) is rapidly expanding its Australian retail footprint with 14 new stores opened or committed in the past 18 months, alongside the full acquisition of Mobile Travel Agents (MTA), Australia's largest home-based travel network. This growth underscores strong confidence in the Helloworld brand and the enduring demand for expert travel advice.
Victor Sage
Victor Sage
28 Aug 2026
Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.
Maxwell Dee
Maxwell Dee
28 Aug 2026
Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.
Ada Torres
Ada Torres
27 Aug 2026
Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.
Ada Torres
Ada Torres
25 Aug 2026
Tungsten Mining has engaged Cutfield Freeman to lead debt financing efforts for its Watershed Tungsten Project, following a robust Preliminary Economic Evaluation and targeting a Final Investment Decision in September 2026.
Maxwell Dee
Maxwell Dee
24 Aug 2026
Li-S Energy reported a reduced net loss of $4.9 million in FY26, propelled by major technological advances and a $7.8 million ARENA grant to scale manufacturing. The company secured key regulatory approvals and expanded strategic defence partnerships, positioning itself at the forefront of sovereign lithium sulfur battery supply.
Victor Sage
Victor Sage
21 Aug 2026
Sparc Technologies launches a $2.5 million capital raise via a Share Purchase Plan and placement to fast-track commercial rollout of its graphene additive ecosparc® and support green hydrogen scale-up.
Sophie Babbage
Sophie Babbage
20 Aug 2026
Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.
Ada Torres
Ada Torres
20 Aug 2026
Energy Fuels Inc. reported a transformative 2024 with a major acquisition boosting its heavy mineral sands assets, a uranium production ramp-up at key US mines, and commercial rare earth oxide output from its White Mesa Mill.
Maxwell Dee
Maxwell Dee
19 Aug 2026
Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.
Ada Torres
Ada Torres
17 Aug 2026
Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.
Ada Torres
Ada Torres
17 Aug 2026
Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.
Ada Torres
Ada Torres
6 Aug 2026

Browse the archive

Full archive